Skip to main content

Table 1 Cohort characteristics according to PE onset*

From: Multivariate joint modeling to identify markers of growth and lung function decline that predict cystic fibrosis pulmonary exacerbation onset

Characteristic at BaselineHad PE during follow up (n = 5510)PE-free during follow up (n = 10,945)Overall (n = 16,455)
Genotype^
 Homozygous53.0%45.6%48.1%
 Heterozygous36.4%39.1%38.2%
 None/unknown10.6%15.3%13.7%
Male sex^47.4%53.7%51.6%
Hispanic9.2%8.5%8.7%
Birth cohort^
  < 198116.7%19.8%18.8%
 1981–198931.6%22.2%25.3%
 1990–199422.0%13.9%16.6%
 1995–199924.6%26.9%26.1%
  > 19995.1%17.2%13.2%
Age at entry, years^8.7 (6.2–13.0)7.9 (6.2–14.0)8.2 (6.2–13.6)
Low SES54.0%52.4%49.8%
MRSA^9.5%6.4%7.4%
Pa^24.2%17.3%19.6%
CFRD^5.1%3.2%3.9%
Pancreatic insufficient^32.3%42.3%39.0%
FEV1, % predicted^83.8 (67.3–98.0)93.5 (79.3–105.2)90.6 (74.9–103.2)
BMIp, percentile^43.1 (19.9–67.0)51.1 (27.3–73.4)48.6 (24.8–71.3)
WFA, percentile^29.1 (10.2–55.0)38.9 (16.7–64.7)35.5 (14.3–61.7)
HFA, percentile^24.5 (8.4–49.8)32.4 (12.3–59.5)29.7 (10.7–56.7)
Length of follow up, years^1.9 (0.5–4.4)3.1 (1.0–6.3)2.6 (0.8–5.7)
Alive^99.9%99.7%99.8%
  1. Abbreviations: BMIp body mass index percentile, CFRD cystic fibrosis related diabetes, FEV1 forced expiratory volume in 1 s, HFA height for age, MRSA methicillin-resistant Staphylococcus aureus, Pa Pseudomonas aeruginosa, PE pulmonary exacerbation, SES socioeconomic status, WFA weight for age. * Values at first recorded entry in the database are used for all patients except for follow-up and death; results for continuous and categorical variables are expressed as median (Q1-Q3) and % over column total, respectively. Characteristics marked as ^ imply P < 0.05 for comparison between PE and PE-free groups. Between-group frequencies compared using Chi-square test of independence; continuous variables compared between groups using Welch two-sample t-test